Overview
JACOBSON PHARMA (2633)
Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the development, production, marketing, and sale of essential medicines and specialty...
- Open
- 0.915
- High
- 0.915
- Low
- 0.905
- Prev. Close
- 0.920
- Volume
- 276.00K
- Turnover
- 250.86K
- Avg Price
- 0.909
- Bid/Ask Ratio
- 94.12%
- Amplitude
- 1.09%
- 52wk High
- 1.400
- Volume Ratio
- 0.53
- Turnover Ratio
- 0.01%
- 52wk Low
- 0.905
- HK Mkt Cap
- 1.81B
- Market CapHKD
- 1.81B
- P/ETTM
- 6.00
- P/EDynamic
- 6.00
- P/EStatic
- --
- EPSTTM
- 0.151
- EPSDynamic
- 0.151
- EPSStatic
- --
- BVPS
- 1.16
- P/B
- 0.78
- HK Shares
- 2.00B
- Dividend YieldTTM
- 9.94%
- DividendTTM
- 0.09
- Shares
- 2.00B
- Min lot size
- 2,000
- Currency
- HKD
JACOBSON PHARMA Analyst Rating
View moreForecast & Rating
Aug 28, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Jacobson Pharma closed at HK$0.905 today, marking a 52-week low that reflects sustained cooling in investor sentiment. The stock has tumbled 29.84% year-to-date from HK$1.29 and trades 39.26% below its 52-week peak of HK$1.49. From a fundamental perspective, Q4 revenue reached HK$401.5 million with 4.7% year-over-year growth; however, operating profit contracted sharply by 11.52% to HK$101.9 million, signaling margin compression. Net profit stood at HK$79.8 million. Market engagement remains subdued, with today's turnover totaling only HK$2.51 million and a turnover rate of just 0.01%, indicating waning investor interest. Technically, the stock has breached its 60-day moving average of HK$0.97 and now trades near the 52-week low support level. On valuation, a P/E of 6.0x and P/B of 0.78x suggest the stock trades below book value; however, the ongoing contraction in operating margins coupled with anemic trading volumes suggest the market lacks conviction in near-term growth prospects.
- Nov, 13
Jacobson Pharma held flat at HK$0.92 today while hitting fresh 52-week lows, with paper-thin trading volume—the morning session saw zero turnover, with merely 16,000 shares transacting in late afternoon. The stock has slumped 28.7% year-to-date and 38.3% from its 52-week high of HK$1.49, reflecting sustained selling pressure and shallow liquidity. Recent quarterly results show operating revenue of HK$401 million, up 4.7% year-over-year, but operating profit declined 11.5%, signaling margin compression. Despite a low valuation—P/E of 6.1x and P/B of 0.79x—the market remains concerned about slowing profit growth and weak investor sentiment.
- Nov, 12
Jacobson Pharma closed marginally lower at HK$0.92 today, declining slightly from the opening price of HK$0.925, reflecting persistent market pessimism. The stock recently hit a 52-week low of HK$0.915, having fallen 28.68% year-to-date and retreated 38.26% from its 52-week peak of HK$1.49, now trading at historic lows. Latest quarterly earnings showed revenue growth of 4.7% year-over-year, yet operating profit declined 11.52% and net profit growth slowed to -0.6%, representing the primary pressure on the stock. Despite an extremely compressed valuation with PE of just 6.1x and PB of 0.79x, plus a 9.78% dividend yield and robust 19.88% net margin, investors remain concerned about the deceleration in earnings growth.
- Nov, 11
Jacobson Pharma held steady at HK$0.920 throughout the session, with both morning and afternoon trading showing minimal activity. The stock recently touched a 52-week low of HK$0.915, and while today's price sits slightly above that floor, it has fallen 28.68% year-to-date from the HK$1.29 opening level and 38.26% below the 52-week high of HK$1.49. On fundamentals, the latest period showed operating revenue growing 4.7% year-on-year to HK$401.5 million with a stable net margin of 19.88%, yet operating profit declined 11.52% and earnings per share slipped 1.17%, indicating earnings pressure. Valuation metrics are compressed at a P/E of 6.1 and P/B of 0.79, near historical lows. However, trading volume has dried up with only 56,000 shares traded and HK$51,520 in daily turnover, reflecting diminished market interest and confidence in the company.
- Nov, 10
Following yesterday's 52-week low of HK$0.915, the stock opened at HK$0.920 this morning and held stable through the morning session, then dipped back to HK$0.915 in afternoon trading before rebounding to close at HK$0.920. The price remains deeply oversold, having declined 28.68% year-to-date and now trading 38.26% below the 52-week high of HK$1.49, well beneath both the 20-day MA of HK$0.942 and 60-day MA of HK$0.977. Latest Q4 results showed operating revenue of HK$401.5 million, up 4.7% YoY, but operating profit of HK$101.9 million fell 11.52% YoY, signaling profitability pressure. With valuation metrics at extremely attractive levels—PE of just 6.1x, PB of 0.79x, and dividend yield of 9.78%—such deep undervaluation may be drawing interest. However, turnover of just 0.01% signals minimal market participation, leaving the sustainability of this rebound uncertain, while improvement in operating margins remains a critical challenge ahead.
News
Market Movers · Jacobson Pharma hits 52-week low
Market Movers · JACOBSON PHARMA hits a new 52-week low, currently trading at $0.92, down approximately 2%
Market Movers · Jacobson Pharma declines 2% in Hong Kong trading
Global Report · Digital Dentistry Bets Spark M&A Wave Among Hong Kong Mid-Caps
PUBT · Jacobson Pharma names Wong Tze Hang independent director, audit committee chair
